Biopharmaceutical innovation continues to accelerate, driven by advances in science, data, and investment. In this exclusive event co-hosted by AlphaSense and Leerink Partners, we explored the evolving landscape of biotech and pharma, with a special focus on targeted oncology and neuroscience. From platform breakthroughs and clinical pipeline trends to regulatory developments and market implications, this conversation unpacked where innovation is headed and what it means for investors and corporate leaders alike.

Featured speakers include Dr. Andrew Berens, Senior Research Analyst at Leerink Partners covering Targeted Oncology, and Marc Goodman, Senior Research Analyst at Leerink Partners covering Neuroscience and Ophthalmology. Together, they shared expert perspectives on the scientific and commercial forces reshaping the life sciences sector and where capital, competition, and clinical progress are converging. Moderated by AlphaSense’s Director of Healthcare Research, Sara Mallatt, this session delivered actionable intelligence for anyone navigating the fast-moving world of life sciences; whether you're tracking market-moving catalysts or positioning your organization for long-term growth.